Close
Visualize HL7 Example and Test Instances (vi7eti), pronounced /viːˈsɛtiː/
Disclaimer: FOR TEST AND EXAMPLE PURPOSES ONLY! These web pages are not intended to be used as a source of information on medicines. The web pages are not kept up to date and are for demonstration purposes only. For up-to-date information on a medicine, please consult www.ema.europa.eu/medicines or the package leaflet of your medicine.
Show source BACK TO LIST

Laboratory Report

Patient
Name: Burns, Jonathan
DOB: 29-JAN-1981 (Age: 44)
Gender: male
Address:
71 High Street
BA22 5XY Ashington (United Kingdom)
ID: 1456-931853-9
Report
Date: 02-NOV-2021
Laboratory
Requested by
Yeovil District Hospital
BA21 3 Yeovil (United Kingdom)
Specimen
Collected: 01-NOV-2021

Chemistry

Test 01 Nov 2021 Reference Range Unit
Hemoglobin A1c/Hemoglobin.total in Blood 5.9 4 - 6 %
Glucose [Mass/volume] in Blood 85.6 70 - 99 mg/dL
Urea nitrogen [Mass/volume] in Blood 20.0 7 - 40 mg/dL
Creatinine [Mass/volume] in Blood 1.3 0.6 - 1.3 mg/dL
Calcium [Mass/volume] in Blood 9.6 8.5 - 10.5 mg/dL
Sodium [Moles/volume] in Blood 136.0 135 - 145 mmol/L
Potassium [Moles/volume] in Blood 4.0 3.5 - 5 mmol/L
Chloride [Moles/volume] in Blood 104.0 98 - 114 mmol/L
Carbon dioxide, total [Moles/volume] in Blood 26.0 22 - 29 mmol/L
Cholesterol [Mass/volume] in Serum or Plasma 281.1 H 0 - 200 mg/dL
Triglyceride [Mass/volume] in Serum or Plasma 145.8 40 - 150 mg/dL
Cholesterol in LDL [Mass/volume] in Serum or Plasma by Direct assay 190.0 H 0 - 100 mg/dL
Cholesterol in HDL [Mass/volume] in Serum or Plasma 61.9 40 - 100 mg/dL

Annotation

Conclusion and Recommendations based on this report and previous findings known to us
The patient shows persistently elevated total and LDL cholesterol, indicating increased cardiovascular risk and need for lipid management. HbA1c is at the upper limit of normal but improved since 2019, suggesting better glycemic control. Renal function, electrolytes, and blood counts are within normal limits except for a previously low erythrocyte count and high platelet distribution width, which may warrant monitoring. Overall, main concerns are dyslipidemia and cardiovascular risk.